AOTI, Inc. earnings date
Want to see GB:AOTI full AI Analyst Report?
AOTI, Inc. (AOTI) Q2 2026 Earnings Report
GB:AOTI Q2 2026 EPS Results
- Actual EPS
- GBP 0.01
- Consensus EPS
- GBP 0.01
- Beat/Miss
- Met expectations
- One Year Ago EPS
- GBP 0.00
GB:AOTI Q2 2026 Revenue Results
- Actual Revenue
- ―
- Expected Revenue
- GBP 26.40M
- Beat/Miss
- ―
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 09/30/2026
- Time
- Before Open
- Conference Call
- Wednesday, September 30, 2026
AOTI, Inc.'s next earnings date is estimated for May 3, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
The call was strongly optimistic, emphasizing 18.8% underlying growth, improved EBITDA margins, positive operating cash flow, clinical evidence, and the potential for CMS coverage to expand the addressable market by 65-fold. The main challenges were unpaid Arizona Medicaid receivables, slower Medicaid expansion, ongoing operational changes, and uncertainty over final Medicare reimbursement. Positive developments and stated opportunities significantly outweighed the disclosed challenges.
For the rest of 2026, AOTI is expecting 2026 EBITDA to be in line with current consensus, which is $6.8 million as at 29th of September, and is confident with its net debt and cash outlook for the full year; it is expecting to continue its top-line growth in line with its guidance set at the time of its FY 2025 results, namely underlying mid-teens growth excluding Arizona Medicaid or low single-digit growth on a reported basis. The company expects to move towards the final LCD within the 365-day period, with the final LCD to complete by July 23rd of next year, and believes average patients per rep, currently around 20, could potentially double in the future, while its highest performing reps produce as much as five times as many as that.
- Robust Underlying Revenue GrowthUnderlying revenue growth was around 18.8%, excluding the Arizona Medicaid segment, while reported revenue growth was 10.8%, driven by the VA and Medicaid businesses.
- Improved EBITDA and MarginsEBITDA grew 16.6% to $3.6 million, and the EBITDA margin improved by 50 basis points to 10.1%. Management attributed the improvement to revenue growth, higher sales-representative productivity, improved gross margins, and changes to the commission scheme.
- Positive Operating Cash Flow and Stable Cash PositionOperating cash flow was positive at $0.9 million, compared with a $4.7 million outflow in the same period last year. Cash at June was $13.8 million versus $13.4 million at year-end, while net debt improved by $0.2 million to $6.3 million.
- VA Business GrowthThe Department of Veterans Affairs business grew 16% and contributed $2.8 million of growth. Management said this was driven by the commercial restructure, improved productivity, and the abating impact of DOGE.
- Medicaid Business GrowthThe Medicaid segment grew 21.5%, primarily driven by New York and New Jersey Medicaid.
- Gross Margin ImprovementGross margin improved by 1.1%, supported by more efficient use of the controller and concentrator fleet and better utilization of consumable stock.
- CMS Coverage MilestoneCMS published a proposed Local Coverage Determination in July stating that topical oxygen is reasonable and necessary for treating Medicare patients. The determination is progressing through the statutory process and is expected to be finalized within the 365-day period, by July 23 of next year.
- Supportive CMS Public Comment ProcessManagement said the 45-day public comment period included an open public comment meeting with universal support for the proposed coverage determination.
- Expansion of Addressable MarketThe current serviceable obtainable market is estimated at approximately 28,000 difficult-to-heal lower-extremity wounds and about $400 million in opportunity, with approximately 6,000 wounds currently served and penetration of less than 20%. Following broader Medicare and related payer coverage, management believes the addressable market could reach about 1.8 million wounds, described as a 65-fold increase.
- Growing Medicaid Market AccessAOTI has expanded to 27 Medicaid states with Medicaid Provider IDs. Management said the related sales presence covers about 27 states and touches about 80% of the U.S. population.
- Evidence Base Strengthened by Real-World StudyA real-world study of more than 3,000 patients, including diabetic foot ulcers, venous leg ulcers, and arterial wounds, showed consistent healing of non-healing wounds, durable healing, and significant reductions in recurrence over greater than 12 months.
- Reported Clinical OutcomesManagement stated that TWO2 heals wounds 6 times more effectively than standard of care, with as much as a sixfold reduction in recurrence over 12 months or longer, more than 80% reductions in hospitalizations, and 70% reductions in amputations during the same period.
- At-Home Outcome-Based PlatformAOTI is building an outcome-based at-home category through its Topical Wound Oxygen therapy, accredited home-care capabilities, and Eyes on the Wound platform. The platform uses data analytics and AI-driven technology to engage patients and provide information to prescribers and payers.
- Sales and Commercial RestructuringThe company changed from sector-specific sales teams to geographic teams covering VA, Medicaid, commercial, and other opportunities in their territories. Management is also applying practices from higher-performing representatives to improve productivity.
- Sales Productivity OpportunityCurrent average productivity is around 20 patients per representative. Management said the highest-performing representatives serve as many as five times that number and believes the average could potentially double over time, without Medicare coverage.
- Planned Venous Leg Ulcer VALUES StudyThe VALUES study is being developed as a double-blinded, placebo-controlled randomized study for venous leg ulcers. The protocol remains in validation, with a limited number of key opinion leader sites currently fine-tuning delivery, and management expects to expand sites across 27 locations.
- Full-Year EBITDA and Growth OutlookManagement expects 2026 EBITDA to be in line with current consensus of $6.8 million as of September 29. The company expects top-line growth in line with prior guidance: underlying mid-teens growth excluding Arizona Medicaid, or low single-digit growth on a reported basis.
- Potential Reimbursement BackstopAOTI is currently reimbursed under a Federal Supply Schedule contract in the VA at approximately $3,000 to $3,100 per month. Management described this as a backstop and said it expects Medicare reimbursement to be somewhere between the VA price and prevailing rates in other sectors, although the final level has not yet been determined.
GB:AOTI Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| May 03, 2027 | 2026 (Q4) | 0.01- | 0.02 | ― | ― |
| Sep 30, 2026 | 2026 (Q2) | 0.010.01 | 0 | ― | |
| Mar 30, 2026 | 2025 (Q4) | 0.010.02 | 0.01 | 13.33% (+0.00) | |
| Sep 22, 2025 | 2025 (Q2) | ―0.00 | -0.04 | 100.00% (+0.04) | |
| Apr 28, 2025 | 2024 (Q4) | ―0.01 | -0.04 | 136.59% (+0.06) | |
| Sep 16, 2024 | 2024 (Q2) | ―-0.04 | -0.02 | -150.00% (-0.02) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

